医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

NeuroMetrix Announces Issuance of Patent for DPNCheck Core Technology in China

2016年09月02日 AM12:44
このエントリーをはてなブックマークに追加


 

WALTHAM, Mass.

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the State Intellectual Property Office of the People’s Republic of China has issued Chinese Patent No. ZL20118055305.7 for the core technology underlying the Company’s DPNCheck® device, which is a point-of-care test for peripheral neuropathies such as diabetic peripheral neuropathy (DPN). The patent claims cover the novel integrated design of the device that enables accurate and rapid measurement of sural nerve conduction, which is a standard neuropathy biomarker. Additional claims cover the automation algorithms and consumable biosensors.

China is dealing with an epidemic of diabetes. According to a recently published study in the Journal of the American Medical Association (JAMA), the prevalence of diabetes in the Chinese population has risen dramatically over the past decades to nearly 12% today. The International Diabetes Federation (IDF) estimated in 2014 that over 96 million people in China had diabetes. This represents nearly 25% of the IDF estimated worldwide population of 387 million people with diabetes.

The Company is partnering with Omron Corporation to introduce DPNCheck to the China healthcare market.

About DPNCheck

DPNCheck is a rapid, accurate and quantitative point-of-care test to detect diabetic peripheral neuropathy at an early stage allowing physicians to select appropriate treatment. DPN is the most common complication of diabetes, affecting over half of people with diabetes. It causes significant morbidity including pain, increased risk of falling in the elderly, and is the primary trigger for diabetic foot ulcers which may require lower extremity amputations. DPNCheck is marketed in the U.S. to Medicare Advantage providers for profiling their patient population as well as guiding treatment. It is marketed in Japan by Omron Healthcare and in Mexico by Scienta Pharma. For product information visit http://www.DPNCheck.com/.

About NeuroMetrix

NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company’s lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs, including a therapeutic device for restless leg syndrome. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160901006006/en/

CONTACT

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Therabiopharma (Japan Based Bio-Venture) Reports 10,000 Times Higher Curcumin Concentration in Bloodstream Clearly Demonstrates Strong Efficacies with/without Oxaliplatin in an Animal Study for Colon Cancer
  • MetLife’s New Blockchain Health Insurance Product Eliminates Claims
  • Murata Invests in MEMS Sensor Manufacturing in Finland
  • Evaluate Ltd: Small Drug Developers Continue to Hold All the Cards, While Young Device Makers Suffer from a Shrinking Pool of Buyers
  • ABLIC Inc. Launches the S-85M0A Series of Ultra-High Efficiency Step-Down Switching Regulators in the Industry’s Most Compact(*) Size